Rakovina Therapeutics Inc.

RKV

CA75103L1013

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 12:59:33 2024-04-25 pm EDT			5-day change	1st Jan Change
0.09 ^CAD	0.00%		-5.26%	+5.88%

Apr. 09	Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	MT
2023	Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	MT

Rakovina Therapeutics Inc. Announces the Transition of Julie Cherrington from the Board of Directors to the Scientific Advisory Board

November 23, 2021 at 05:25 pm EST

Rakovina Therapeutics Inc. announced the transition of Dr. Julie Cherrington from the Board of Directors to the Scientific Advisory Board.

Latest news about Rakovina Therapeutics Inc.

Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	Apr. 09	MT
Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	Nov. 27	MT
Rakovina Therapeutics Appoints Prof. Artem Cherkasov to the Scientific Advisory Board	Nov. 27	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 26	CI
Rakovina Therapeutics Inc. Announces Appointment of Prof. Petra Hamerlik as New Scientific Advisory Board Member	Nov. 20	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Rakovina Therapeutics Inc. announced that it has received CAD 1.5 million in funding	23-05-28	CI
Rakovina Therapeutics Inc. announced that it expects to receive CAD 1.5 million in funding	23-05-01	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting	23-04-20	MT
Rakovina Therapeutics Inc. Announces Presentation of New KT-3000 Series Data At AACR Annual Meeting	23-04-20	CI
Rakovina Therapeutics Receives Federal Funding to Accelerate Development of Novel Cancer Therapies	23-03-22	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15	CI
Rakovina Therapeutics Says Publication Highlights Activity of Dual PARP-HDAC Inhibitor in Models of Ewing Sarcoma	22-11-14	MT
Rakovina Therapeutics Presented Preclinical Data at Molecular Targets and Cancer Therapeutics Symposium in Barcelona	22-10-31	MT
Rakovina Therapeutics Second-Quarter Loss Narrows on Lower Spending	22-08-11	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas	22-05-11	CI
Rakovina Therapeutics Reports Q4 Net Loss of $751K	22-04-27	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Rakovina Therapeutics Presents Preclinical Data For kt-4000 Series Compounds at AACR Annual Meeting	22-04-12	MT
Rakovina Therapeutics Presents Evaluation of A Novel Class of Bifunctional DNA Alkylating PARP Inhibitors	22-04-12	CI
Rakovina Therapeutics to Present Abstract at Annual Meeting of the American Association of Cancer Research	22-03-09	MT

Chart Rakovina Therapeutics Inc.

Duration

Period

More charts

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Companyâs research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cellâs DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.

Sector

Biotechnology & Medical Research

Calendar

2024-04-25 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RAKOVINA THERAPEUTICS INC.	+5.88%	4.6M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B